Galmed Pharmaceuticals Ltd.

GLMDSEC EDGAR

Pharmaceutical Preparations(L3)CIK: 1595353

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Revenues	—	—	—	—	$2.0M
Research and Development Expense	$13.0M	$27.2M	$26.1M	$18.2M	$8.3M
Operating Expenses	$17.7M	$32.9M	$30.2M	$22.4M	—
Operating Income (Loss)	—	—	—	—	-$10.7M
Nonoperating Income (Expense)	—	—	—	—	—
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	$17.9M	-$32.5M	-$28.8M	-$20.5M	—
Income Tax Expense (Benefit)	—	—	—	—	$75.0K
Net Income (Loss) Attributable to Parent

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Assets	$16.6M	$16.6M	$36.6M	$52.4M	$77.1M
Assets, Current	$13.2M	$14.7M	$36.1M	$51.8M	$76.4M
Cash and Cash Equivalents, at Carrying Value	$2.9M	$2.0M	$2.9M	$6.9M	$15.9M
Liabilities, Current	$2.8M	$3.1M	$5.9M	$8.0M	$6.9M
Long-term Debt, Excluding Current Maturities	—	—	—	—	—
Accounts Payable, Current	$1.9M	$2.6M	$4.9M	$7.0M	—
Stockholders' Equity Attributable to Parent	$30.5M	$44.2M	$69.9M	$69.9M

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Net Cash Provided by (Used in) Operating Activities	-$18.5M	-$32.9M	-$26.3M	-$14.9M	-$9.0M
Net Cash Provided by (Used in) Investing Activities	$17.6M	$11.5M	$16.5M	$6.7M	-$60.0M
Net Cash Provided by (Used in) Financing Activities	$70.0K	$17.4M	$768.0K	$143.0K	$80.2M
Payments to Acquire Property, Plant, and Equipment	$4.0K	$11.0K	$44.0K	$12.0K	$90.0K

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)